Defining the Global Landscape of Kidney Genetics Care-A Scoping Review and International Stakeholder Consultation of Clinic Models and Outcomes

This scoping review and international stakeholder consultation characterize the global landscape of kidney genetics care, identifying four distinct clinic models and regional variations in funding and testing strategies while emphasizing that effective implementation and diagnostic success depend more on patient selection and support structures than on the specific testing modality used.

The Gist

Imagine your body's kidneys as a highly sophisticated factory. Sometimes, the factory stops working because of a broken machine part that was built wrong from the very beginning—a "blueprint error" in your DNA. For a long time, doctors could see the factory was broken but couldn't read the blueprint to fix it.

Now, we have a new tool: Genetic Testing. It's like a super-powered magnifying glass that reads the blueprint to find the exact error. But here's the problem: How do we actually set up the "Genetic Detective Agency" to read these blueprints?

This paper is a global report card on how different countries are building these detective agencies. The authors didn't just look at textbooks; they read 60 research stories and asked 48 real-life "clinic bosses" from around the world, "How does your agency work?"

Here is the breakdown of their findings, using some everyday analogies:

1. The Four Types of Detective Agencies (Clinic Models)

The researchers found that countries are building their genetic clinics in four different ways:

• The "All-Star Team" (Multidisciplinary Integrated): This is like a high-end hospital where a kidney doctor, a genetics expert, and a counselor all sit in the same room. They huddle together, look at the patient, and solve the puzzle instantly. This is the most common model in Europe, Australia, and New Zealand.
• The "Specialized Kidney Doctor" (Nephrologist-Led): Here, the kidney doctor has taken extra classes to become a genetics expert. They run the show, often with a counselor helping out. This is very common in North America and parts of Asia. It's like a general contractor who also knows how to fix the electrical wiring.
• The "Mainstreaming" Model: This is when the genetic testing is just added to a regular kidney check-up, like adding a new topping to a pizza. It's less common but growing.
• The "Old School Referral" Model: You go to your kidney doctor, they say, "I don't know, go see the genetics guy over there." This is the traditional way, but it's becoming less popular because it's slow and clunky.

2. The Global Map: Who is Doing What?

• Europe & Australia/New Zealand: They are running the "All-Star Team" model. They have strong public funding (like a government grant), so they can afford to hire all the experts and use the most advanced "scanners" (Whole Genome Sequencing) to read the entire blueprint.
• North America: They are more like a mix of "Specialized Doctors" and "All-Star Teams." Because of how insurance works there, they often rely on private labs and sometimes have to pick and choose which parts of the blueprint to read first (Targeted Panels) to save money.
• Asia: They are trying hard, but they often face "resource constraints." It's like trying to build a high-tech lab with a limited budget. Often, one very smart kidney doctor has to do the job of three people because there aren't enough specialists available.

3. The Big Surprise: It's Not About the Tool, It's About the Detective

You might think the most expensive, high-tech scanner (reading the entire DNA blueprint) would find the most errors. The study found that this isn't necessarily true.

• The Analogy: Imagine looking for a lost key in a messy room.
  • Scanner A looks at the whole room at once (Whole Genome Sequencing).
  • Scanner B looks only at the table where you usually drop keys (Targeted Panel).
  • The Result: If the detective (the doctor) knows exactly where to look based on the patient's symptoms, Scanner B finds the key just as often as Scanner A.
• The Lesson: The most important thing isn't the fancy machine; it's patient selection. If the doctor picks the right patients (those whose symptoms strongly suggest a blueprint error), they will find the answer regardless of which test they use.

4. What's Missing? (The Blind Spots)

The study found that while everyone is good at counting how many "keys" they found (Diagnostic Yield), they are terrible at measuring the rest of the experience.

• The "Wait Time" Blind Spot: We don't know how long patients sit in the waiting room.
• The "Happiness" Blind Spot: We rarely ask patients, "Did you feel supported? Was this scary for you?"
• The "Implementation" Blind Spot: We don't know if the system is actually sustainable or if it's just a lucky one-off success.

The Bottom Line

Kidney genetics is a booming field, but it's like a patchwork quilt—some parts are high-tech and well-funded, while others are struggling with limited resources.

The Takeaway:
To fix kidney diseases caused by genetic errors, we don't need a "one-size-fits-all" solution.

• If you have the money and staff, build an All-Star Team.
• If you have limited staff, train your Kidney Doctors to be the experts.
• Crucially: Focus on picking the right patients to test. A smart detective with a simple magnifying glass is often better than a confused detective with a super-computer.

The authors are calling for a global effort to standardize how we measure success—not just by how many diagnoses we make, but by how happy, safe, and well-supported our patients feel along the journey.

Technical Summary

1. Problem Statement

Despite the rapid advancement of genomic sequencing and its proven utility in diagnosing kidney diseases, the real-world implementation of kidney genetics services remains fragmented, inconsistent, and poorly characterized. Key challenges include:

• Lack of Standardization: There is no consensus on the optimal structure of kidney genetics clinics (e.g., team composition, referral pathways).
• Implementation Gaps: Barriers such as workforce limitations, regulatory constraints, and funding models hinder integration into routine nephrology care.
• Evidence Deficit: Existing literature focuses heavily on diagnostic yield but lacks data on patient-reported outcomes, implementation success (e.g., timeliness, sustainability), and comparative effectiveness of different care models across diverse global settings.
• Geographic Inequity: Evidence is heavily skewed toward high-income countries, leaving a knowledge gap regarding service delivery in low- and middle-income regions.

2. Methodology

The authors conducted a two-part scoping study to map the global landscape of kidney genetics care:

Part 1: Scoping Literature Review

• Protocol: Registered on the Open Science Framework (OSF) and conducted following Joanna Briggs Institute (JBI) and PRISMA-ScR guidelines.
• Search Strategy: Comprehensive search of MEDLINE, Scopus, Embase, and Google Scholar for English-language publications between January 2000 and February 2025.
• Selection: From 4,375 initial citations, 60 studies met inclusion criteria.
• Analysis: Data were synthesized using thematic analysis. A taxonomy of clinic models was developed based on team composition, referral pathways, and testing authority. Outcomes were mapped to the Institute of Medicine (IOM) quality framework and Proctor's implementation outcomes taxonomy.

Part 2: International Stakeholder Consultation

• Participants: 48 kidney genetics clinic leads from five global regions (Australia/New Zealand, UK/Ireland, North America, Europe, Asia).
• Instrument: A 42-item structured survey covering clinic structure, patient populations, testing strategies, laboratory partnerships, and funding models.
• Triangulation: Findings from the literature review were triangulated with survey data to identify convergences, divergences, and gaps between published reports and current real-world practice.

3. Key Contributions

• First Global Taxonomy: Established a standardized classification of kidney genetics clinic models into four distinct types:
  1. Multidisciplinary Integrated: Nephrologists, geneticists, and counselors working concurrently.
  2. Nephrologist-Led: Genetics-trained nephrologists leading the service with genetic counselor support.
  3. Mainstreaming: Genetic testing integrated into general nephrology pathways.
  4. Traditional Genetics Referral: Standard referral to clinical genetics services.
• Real-World Data Integration: Combined published literature (n=60) with contemporaneous stakeholder insights (n=48) to provide a more complete picture of current service delivery than literature alone.
• Outcome Framework Application: Systematically applied implementation science frameworks to evaluate not just diagnostic yield, but also penetration, timeliness, and sustainability.

4. Key Results

Geographic and Temporal Trends

• Literature Bias: 60 included studies were predominantly from North America (n=23), Europe (n=17), and Australia/New Zealand (n=10). Asia (n=5) and other regions were underrepresented.
• Evolution: Multidisciplinary clinics were the first to be published (2016), but nephrologist-led models have grown rapidly since 2020.

Clinic Models and Structure

• Dominant Models: Multidisciplinary clinics are the most common globally (especially in AUS/NZ and Europe), but nephrologist-led models are increasingly prevalent, particularly in North America.
• Team Composition:
  • AUS/NZ, UK/Ireland, EU: Typically multidisciplinary teams including clinical geneticists and genetic counselors.
  • North America: Often nephrologist-led with genetic counselor support; less routine involvement of clinical geneticists.
  • Asia: Resource-constrained; often led by a single genetics-trained nephrologist due to a lack of genetic counselors.

Testing Strategies and Laboratories

• Testing Approach:
  • AUS/NZ, UK, EU: Predominantly use comprehensive sequencing (Whole Exome/Genome Sequencing - WES/WGS) with virtual panels.
  • North America: More likely to use phenotype-driven targeted panels with reflex to WES/WGS.
• Laboratories:
  • UK/Ireland: Primarily public/in-house or national labs.
  • North America: Heavy reliance on commercial laboratories.
  • AUS/NZ: Mixed use of in-house, commercial, and hybrid models.

Funding

• Public vs. Private: Public funding predominates in the UK/Ireland (92%) and is common in AUS/NZ (81%) and Europe (57%). North America relies heavily on private payers (insurance/out-of-pocket).

Outcomes: Yield vs. Penetration

• Diagnostic Yield: Highly variable (26%–67%). European programs reported the highest yields (57–67%), attributed to standardized referral criteria, deep phenotyping, and multidisciplinary review.
• Test Penetration: Generally high across all regions (66–100%), indicating that once patients are offered testing, they largely complete it.
• Model Comparison: Nephrologist-led clinics demonstrated comparable diagnostic yield and penetration to multidisciplinary models when adequately supported (training, governance, counseling).
• Testing Modality: Diagnostic yield appeared more dependent on patient selection and phenotyping than the specific testing modality (targeted panel vs. WES/WGS).

Reporting Gaps

• Imbalance: 92% of studies reported diagnostic yield.
• Missing Data: Only 16% reported timeliness, 12% reported patient satisfaction, and 4% assessed implementation fidelity. There is a critical lack of data on patient-reported outcomes and health economics.

5. Significance and Implications

• Scalability: The findings suggest that nephrologist-led models are a viable, scalable alternative to resource-intensive multidisciplinary clinics, provided they have formal training, embedded counseling, and decision-support governance.
• Contextual Fit: There is no "one-size-fits-all" model. Successful implementation requires aligning clinic structure, testing strategy, and funding with local health system capabilities and workforce availability.
• Patient Selection: Meticulous phenotyping and patient selection are more critical determinants of diagnostic success than the choice of genetic test (panel vs. sequencing).
• Future Directions: The study calls for:
  1. Standardized Reporting: Mandatory reporting of denominators, time-to-diagnosis, and implementation outcomes (acceptability, feasibility, sustainability).
  2. Theory-Informed Evaluation: Moving from descriptive studies to prospective, mixed-methods implementation research.
  3. Equity: Urgent need to expand services and research in underrepresented regions (Asia, Africa, South America) to address global disparities in kidney care.

In conclusion, while kidney genetics care is expanding, it remains uneven. The study provides a roadmap for developing equitable, sustainable, and context-specific genomic services by validating diverse clinic models and highlighting the need for broader outcome measurement beyond diagnostic yield.